BRPI0818003A2 - inibidores de csf-1r, composições e métodos de uso - Google Patents

inibidores de csf-1r, composições e métodos de uso

Info

Publication number: BRPI0818003A2
Authority: BR; Brazil
Prior art keywords: csf; inhibitors; compositions; methods
Prior art date: 2007-10-18

Application number

BRPI0818003A

Other languages

English (en)

Inventor

Sutton James

Sendzik Martin

Wang Weibo

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-18

Filing date

2008-10-16

Publication date

2019-09-24

2008-10-16 Application filed by Novartis Ag filed Critical Novartis Ag

2019-09-24 Publication of BRPI0818003A2 publication Critical patent/BRPI0818003A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0818003A 2007-10-18 2008-10-16 inibidores de csf-1r, composições e métodos de uso BRPI0818003A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98105807P	2007-10-18	2007-10-18
PCT/EP2008/063952 WO2009050228A2 (en)	2007-10-18	2008-10-16	Csf-1r inhibitors for treatment of cancer and bone diseases

Publications (1)

Publication Number	Publication Date
BRPI0818003A2 true BRPI0818003A2 (pt)	2019-09-24

Family

ID=40184889

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0818003A BRPI0818003A2 (pt)	2007-10-18	2008-10-16	inibidores de csf-1r, composições e métodos de uso

Country Status (11)

Country	Link
US (1)	US20100261679A1 (pt)
EP (1)	EP2211862A2 (pt)
JP (1)	JP2011500635A (pt)
KR (1)	KR20100072075A (pt)
CN (1)	CN101801379A (pt)
AU (1)	AU2008313727A1 (pt)
BR (1)	BRPI0818003A2 (pt)
CA (1)	CA2702699A1 (pt)
EA (1)	EA201000620A1 (pt)
MX (1)	MX2010004246A (pt)
WO (1)	WO2009050228A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR075180A1 (es) *	2009-01-29	2011-03-16	Novartis Ag	Formulaciones orales solidas de una pirido-pirimidinona
PT2566517T (pt)	2010-05-04	2019-01-24	Five Prime Therapeutics Inc	Anticorpos que ligam csf1r
CA2800664C (en) *	2010-06-01	2019-09-24	Angion Biomedica Corp.	Benzothiazole cytochrome p450 inhibitors and therapeutic uses thereof
WO2013011021A1 (en) *	2011-07-18	2013-01-24	The University Of Melbourne	Use of c-fms antagonists
KR102066297B1 (ko) *	2011-10-14	2020-01-14	암비트 바이오사이언시즈 코포레이션	헤테로사이클릭 화합물 및 이의 유형 3 수용체 티로신 키나아제의 조절인자로서의 용도
SG11201606080SA (en)	2014-02-03	2016-08-30	Vitae Pharmaceuticals Inc	Dihydropyrrolopyridine inhibitors of ror-gamma
CN107074852B (zh)	2014-10-14	2019-08-16	生命医药有限责任公司	ROR-γ的二氢吡咯并吡啶抑制剂
US9845308B2 (en)	2014-11-05	2017-12-19	Vitae Pharmaceuticals, Inc.	Isoindoline inhibitors of ROR-gamma
US9663515B2 (en)	2014-11-05	2017-05-30	Vitae Pharmaceuticals, Inc.	Dihydropyrrolopyridine inhibitors of ROR-gamma
HK1245804A1 (zh)	2014-12-22	2018-08-31	Five Prime Therapeutics, Inc.	用於治疗pvns的抗csf1r抗体
EP3294417B1 (en)	2015-05-08	2021-10-13	Memorial Sloan Kettering Cancer Center	Compositions and methods for treatment of glioma
US10301261B2 (en)	2015-08-05	2019-05-28	Vitae Pharmaceuticals, Llc	Substituted indoles as modulators of ROR-gamma
EP3377482B1 (en)	2015-11-20	2021-05-12	Vitae Pharmaceuticals, LLC	Modulators of ror-gamma
TWI757266B (zh)	2016-01-29	2022-03-11	美商維它藥物有限責任公司	ＲＯＲ－γ調節劑
US9481674B1 (en)	2016-06-10	2016-11-01	Vitae Pharmaceuticals, Inc.	Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2018178852A1 (en) *	2017-03-28	2018-10-04	Novartis Ag	New methods for the treatment of multiple sclerosis
EP3632906B1 (en) *	2017-05-24	2023-12-13	Abbisko Therapeutics Co., Ltd.	Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy
CN108329306A (zh) *	2017-07-09	2018-07-27	曹艳	一种用于治疗艾滋病药物的制备方法
WO2019018975A1 (en)	2017-07-24	2019-01-31	Vitae Pharmaceuticals, Inc.	INHIBITORS OF ROR GAMMA
MA49685A (fr)	2017-07-24	2021-04-14	Vitae Pharmaceuticals Llc	INHIBITEURS DE ROR gamma
AU2019227607C1 (en)	2018-02-27	2023-07-20	Incyte Corporation	Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
CN112368270B (zh) *	2018-04-12	2023-10-13	卫材R&D管理有限公司	作为用于治疗癌症的剪接体靶向剂的普拉二烯内酯衍生物
MX2020012376A (es)	2018-05-18	2021-03-09	Incyte Corp	Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
US11161850B2 (en)	2018-07-05	2021-11-02	Incyte Corporation	Fused pyrazine derivatives as A2A / A2B inhibitors
TWI816881B (zh) *	2018-09-13	2023-10-01	大陸商恒翼生物醫藥（上海）股份有限公司	用於治療三陰性乳癌之組合療法
US12415816B2 (en)	2018-11-07	2025-09-16	Dana-Farber Cancer Institute, Inc.	Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12522583B2 (en)	2018-11-07	2026-01-13	Dana-Farber Cancer Institute, Inc.	Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097400A1 (en)	2018-11-07	2020-05-14	Dana-Farber Cancer Institute, Inc.	Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
CN109364252B (zh) *	2018-11-21	2021-09-28	南京大学	抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
EP4146639A1 (en)	2020-05-06	2023-03-15	Ajax Therapeutics, Inc.	6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202241889A (zh)	2020-12-23	2022-11-01	美商雅捷可斯治療公司	作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
WO2023086319A1 (en)	2021-11-09	2023-05-19	Ajax Therapeutics, Inc.	6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202325289A (zh)	2021-11-09	2023-07-01	美商雅捷可斯治療公司	Ｊａｋ２抑制劑之形式及組合物
KR102862736B1 (ko) *	2022-12-07	2025-09-22	부산대학교 산학협력단	신규 2-((트랜스-4-(4-아릴옥시)사이클로헥실)아미노)퀴나졸리논 유도체 및 이의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8299108B2 (en) *	2002-03-29	2012-10-30	Novartis Ag	Substituted benzazoles and methods of their use as inhibitors of raf kinase
US7071216B2 (en) *	2002-03-29	2006-07-04	Chiron Corporation	Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
AU2004281154A1 (en) *	2003-10-16	2005-04-28	Novartis Vaccines And Diagnostics, Inc.	2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer
AU2004281151A1 (en) *	2003-10-16	2005-04-28	Novartis Vaccines And Diagnostics, Inc.	Substituted benzazoles and use thereof as inhibitors of Raf kinase
MY139645A (en) *	2004-02-11	2009-10-30	Amgen Inc	Vanilloid receptor ligands and their use in treatments
US7576090B2 (en) *	2004-12-27	2009-08-18	4Sc Ag	Benzazole analogues and uses thereof
AU2007237904B2 (en) *	2006-04-19	2011-03-03	Novartis Ag	6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling

2008
- 2008-10-16 CA CA2702699A patent/CA2702699A1/en not_active Abandoned
- 2008-10-16 MX MX2010004246A patent/MX2010004246A/es not_active Application Discontinuation
- 2008-10-16 EA EA201000620A patent/EA201000620A1/ru unknown
- 2008-10-16 CN CN200880106381A patent/CN101801379A/zh active Pending
- 2008-10-16 EP EP08840488A patent/EP2211862A2/en not_active Withdrawn
- 2008-10-16 AU AU2008313727A patent/AU2008313727A1/en not_active Abandoned
- 2008-10-16 US US12/738,277 patent/US20100261679A1/en not_active Abandoned
- 2008-10-16 BR BRPI0818003A patent/BRPI0818003A2/pt not_active IP Right Cessation
- 2008-10-16 JP JP2010529382A patent/JP2011500635A/ja active Pending
- 2008-10-16 WO PCT/EP2008/063952 patent/WO2009050228A2/en not_active Ceased
- 2008-10-16 KR KR1020107010721A patent/KR20100072075A/ko not_active Withdrawn

Also Published As

Publication number	Publication date
EP2211862A2 (en)	2010-08-04
AU2008313727A8 (en)	2010-04-22
EA201000620A1 (ru)	2010-12-30
WO2009050228A3 (en)	2009-07-30
AU2008313727A1 (en)	2009-04-23
CA2702699A1 (en)	2009-04-23
US20100261679A1 (en)	2010-10-14
JP2011500635A (ja)	2011-01-06
WO2009050228A2 (en)	2009-04-23
MX2010004246A (es)	2010-04-30
KR20100072075A (ko)	2010-06-29
CN101801379A (zh)	2010-08-11

Publication	Publication Date	Title
BRPI0818003A2 (pt)	2019-09-24	inibidores de csf-1r, composições e métodos de uso
BRPI0812159A2 (pt)	2017-05-02	inibidores de csf-1r, composições e métodos de uso
BRPI0813627A2 (pt)	2014-12-23	Peptídio antimicrobiano, composições e métodos de uso
BRPI0920263A2 (pt)	2016-07-12	composto, uso do composto, composição, e, método
CY2019010I2 (el)	2019-11-27	Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης
BRPI0911688A2 (pt)	2015-07-28	"compostos de pirimidina, composições e métodos de uso"
BRPI0913086A2 (pt)	2015-08-04	Composições antimicrobianas e métodos de uso
SMT201500213B (it)	2015-10-30	Alcune triazolopirazine, loro composizioni e metodi d'uso
SMT201600388B (it)	2017-03-08	Ligandi leganti opsina, composizioni e metodi d'uso
PT2585437E (pt)	2014-04-29	Compostos de tioacetato, composições e métodos de uso
SMT201400181B (it)	2015-01-15	Composizioni per vasocostrizione e metodi d'uso
BRPI0915231A2 (pt)	2018-06-12	compostos inibidores de quinase e métodos de uso
BRPI0911332A2 (pt)	2019-09-24	composições e uso de inibidores de epas1
PL2215071T3 (pl)	2015-12-31	Proleki tetrahydrokannabinolu, kompozycje zawierające proleki tetrahydrokannabinolu i sposoby ich stosowania
BR112013006016A2 (pt)	2016-06-07	compostos de azabenzotiazol, composições e métodos de uso
BRPI0816350A2 (pt)	2015-02-24	Composições orais, produtos e métodos de uso
PT2424372T (pt)	2018-04-19	Composições antimicrobianas e métodos de uso relacionados
BRPI0908792A2 (pt)	2015-07-21	Composição, e, uso de uma combinação
DOP2011000059A (es)	2011-05-15	Composiciones de antagonistas de pd-1 y metodos de uso
BRPI0915928A2 (pt)	2015-11-03	composições e métodos de uso para anticorpos terapêuticos
PL2356462T3 (pl)	2017-07-31	Kompozycje anty-CXCR1 oraz sposoby
BRPI0916769A2 (pt)	2017-09-26	derivados de benzilbenzeno deuterados e métodos de uso
BRPI0913739A2 (pt)	2015-08-18	Composição líquida, método, e, uso de composição
BRPI0813770A2 (pt)	2014-12-30	Composição, e, uso de uma composição
BRPI0717411A2 (pt)	2013-11-12	Uso de inibidores de iap

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2020-01-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.